Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Savara Inc SVRA

Healthcare Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. see more

Current News (NDAQ:SVRA)

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Business Wire 14 hours ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Business Wire 7 days ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Business Wire 9 days ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Business Wire February 20, 2026

Savara Announces New Employment Inducement Grant

Business Wire February 13, 2026

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Business Wire February 4, 2026

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Business Wire January 27, 2026

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire January 24, 2026

Savara Announces New Employment Inducement Grant

Business Wire January 16, 2026
View More News ››

Opinion & Analysis (NDAQ:SVRA)

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Streetwise Reports January 2, 2020
View More Opinion ››

Bullboard Posts (NDAQ:SVRA)

it's a buy today for me

at $3.37 per share,it looks like a this one will make a comeback and it was on my watchlist,so glta.
coolfooldumbguy - December 30, 2019

the bottom is past for

this one, I was really out of it today,so glta as I will try to stay sober for the rest of the week.
coolfooldumbguy - June 19, 2019

watching this one for

an entry point,so glta.
coolfooldumbguy - June 18, 2019
View more Bullboard ››

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds the Summit Gold ...
View More »

Podcasts